{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:44:20Z","timestamp":1791229460706,"version":"4.1.0"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.2215\/cjn.01760215","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T22:35:17Z","timestamp":1438209317000},"page":"161-174","source":"Crossref","is-referenced-by-count":57,"title":["Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism"],"prefix":"10.2215","volume":"11","author":[{"given":"Jordi","family":"Bover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ure\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Ruiz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iara","family":"daSilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lescano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"del Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Ballar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-22-20230601","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R4-22-20230601","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.semnephrol.2014.09.006","article-title":"News on biomarkers in CKD-MBD.","volume":"34","author":"Mazzaferro","year":"2014","journal-title":"Semin Nephrol"},{"key":"R5-22-20230601","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.semnephrol.2014.09.008","article-title":"Adynamic bone disease: From bone to vessels in chronic kidney disease.","volume":"34","author":"Bover","year":"2014","journal-title":"Semin Nephrol"},{"key":"R6-22-20230601","first-page":"3","article-title":"Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.).","volume":"31","author":"Torregrosa","year":"2011","journal-title":"Nefrologia"},{"key":"R7-22-20230601","first-page":"108","article-title":"Clinical practice guideline for chronic kidney disease-mineral and bone disease (2010 version).","volume":"32","author":"Prados-Garrido","year":"2011","journal-title":"Dial Traspl"},{"key":"R8-22-20230601","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfv020","article-title":"Pro: Cardiovascular calcifications are clinically relevant.","volume":"30","author":"Bover","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R9-22-20230601","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"R10-22-20230601","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis.","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"R11-22-20230601","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R12-22-20230601","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gfs356","article-title":"Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study.","volume":"28","author":"Ure\u00f1a-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R13-22-20230601","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"R14-22-20230601","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/ndt\/gfv019","article-title":"Moderator\u2019s view: Treatment of vascular calcification is a physical impossibility, so far.","volume":"30","author":"Wanner","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R15-22-20230601","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1185\/03007990903399398","article-title":"Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.","volume":"25","author":"Wilson","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R16-22-20230601","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","article-title":"Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trials.","volume":"54","author":"Navaneethan","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R17-22-20230601","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/kisup.2011.28","article-title":"Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: New insights into vitamin D receptor activation.","volume":"1","author":"Bover","year":"2011","journal-title":"Kidney Int Suppl (2011"},{"key":"R18-22-20230601","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"R19-22-20230601","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ndt\/gfn492","article-title":"Mortality reduction by vitamin D receptor activation in end-stage renal disease: A commentary on the robustness of current data.","volume":"24","author":"Vervloet","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R20-22-20230601","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000346846","article-title":"Vitamin D treatment and mortality in chronic kidney disease: A systematic review and meta-analysis.","volume":"37","author":"Duranton","year":"2013","journal-title":"Am J Nephrol"},{"key":"R21-22-20230601","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"R22-22-20230601","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/ndt\/gft514","article-title":"Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R23-22-20230601","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"R24-22-20230601","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options.","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R25-22-20230601","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.semnephrol.2014.09.004","article-title":"When, how, and why a bone biopsy should be performed in patients with chronic kidney disease.","volume":"34","author":"Torres","year":"2014","journal-title":"Semin Nephrol"},{"key":"R26-22-20230601","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2215\/CJN.06661208","article-title":"Bone-vascular axis in chronic kidney disease: A reality?","volume":"4","author":"London","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-22-20230601","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(14)70059-2","article-title":"Bone: A new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders.","volume":"2","author":"Vervloet","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R28-22-20230601","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.03520414","article-title":"Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis.","volume":"10","author":"Ishani","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R29-22-20230601","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2215\/CJN.07050714","article-title":"A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM).","volume":"10","author":"Wetmore","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R30-22-20230601","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ndt\/gfv050","article-title":"Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.","volume":"30","author":"Goldsmith","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R31-22-20230601","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1152\/physrev.1991.71.2.371","article-title":"Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers.","volume":"71","author":"Brown","year":"1991","journal-title":"Physiol Rev"},{"key":"R32-22-20230601","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor.","volume":"95","author":"Nemeth","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R36-22-20230601","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gft417","article-title":"Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.","volume":"29","author":"Martin","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R37-22-20230601","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.","volume":"85","author":"Martin","year":"2014","journal-title":"Kidney Int"},{"key":"R38-22-20230601","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.","volume":"53","author":"Chonchol","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R39-22-20230601","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1440-1797.2011.01530.x","article-title":"Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.","volume":"17","author":"Montenegro","year":"2012","journal-title":"Nephrology (Carlton"},{"key":"R40-22-20230601","first-page":"171","article-title":"Hiperparatiroidismo aut\u00f3nomo en paciente renal cr\u00f3nico estadio 3.","volume":"34","author":"DaSilva","year":"2013","journal-title":"Dial Transplant"},{"key":"R41-22-20230601","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/EJE-14-0355","article-title":"The PRIMARA study: A prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice.","volume":"171","author":"Schwarz","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"R42-22-20230601","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nep.12186","article-title":"Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: A multicentre, retrospective, 3-year study.","volume":"19","author":"Torregrosa","year":"2014","journal-title":"Nephrology (Carlton"},{"key":"R43-22-20230601","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/ajt.12911","article-title":"A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism.","volume":"14","author":"Evenepoel","year":"2014","journal-title":"Am J Transplant"},{"key":"R44-22-20230601","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R45-22-20230601","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium \u00d7 phosphorus in secondary hyperparathyroidism.","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"R46-22-20230601","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"R47-22-20230601","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study.","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R48-22-20230601","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"R49-22-20230601","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"R50-22-20230601","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.00870805","article-title":"Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium \u00d7 phosphate.","volume":"1","author":"Chertow","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R51-22-20230601","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","article-title":"Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.","volume":"23","author":"Block","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R52-22-20230601","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: Assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism.","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R53-22-20230601","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results.","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R54-22-20230601","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/ndt\/gfl840","article-title":"Implementation of \u2018K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease\u2019 after the introduction of cinacalcet in a population of patients on chronic haemodialysis.","volume":"22","author":"Arenas","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R55-22-20230601","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","article-title":"Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.","volume":"24","author":"Ure\u00f1a","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R56-22-20230601","doi-asserted-by":"crossref","first-page":"c109","DOI":"10.1159\/000319882","article-title":"Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: An observational study in routine clinical practice.","volume":"118","author":"Bover","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"R57-22-20230601","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CNP69269","article-title":"An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.","volume":"69","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"key":"R58-22-20230601","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int"},{"key":"R59-22-20230601","doi-asserted-by":"crossref","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.","volume":"10","author":"Palmer","year":"2013","journal-title":"PLoS Med"},{"key":"R60-22-20230601","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R61-22-20230601","doi-asserted-by":"crossref","first-page":"e001363","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"R62-22-20230601","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial.","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R63-22-20230601","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJMc1301247","article-title":"Cinacalcet for cardiovascular disease in patients undergoing dialysis.","volume":"368","author":"Urena-Torres","year":"2013","journal-title":"N Engl J Med"},{"key":"R64-22-20230601","first-page":"1843","article-title":"Cinacalcet for cardiovascular disease in patients undergoing dialysis.","volume":"368","author":"Locatelli","year":"2013","journal-title":"N Engl J Med"},{"key":"R65-22-20230601","doi-asserted-by":"crossref","first-page":"e48070","DOI":"10.1371\/journal.pone.0048070","article-title":"Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: A meta-analysis.","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"R66-22-20230601","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12020-012-9711-2","article-title":"The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: A meta-analysis.","volume":"43","author":"Li","year":"2013","journal-title":"Endocrine"},{"key":"R67-22-20230601","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2010.10.041","article-title":"Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007.","volume":"57","author":"Li","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R68-22-20230601","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: Results of the IMPACT SHPT study.","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R69-22-20230601","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2013-2975","article-title":"The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial.","volume":"98","author":"Parfrey","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R70-22-20230601","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","article-title":"KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).","volume":"55","author":"Uhlig","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R71-22-20230601","first-page":"348","article-title":"Cinacalcet for secondary hyperparathyroidism: From improved mineral levels to improved mortality?","volume":"71","author":"Vervloet","year":"2013","journal-title":"Neth J Med"},{"key":"R72-22-20230601","doi-asserted-by":"crossref","first-page":"F1390","DOI":"10.1152\/ajprenal.00262.2006","article-title":"The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands.","volume":"292","author":"Rodriguez","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R73-22-20230601","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1093\/ndt\/gfn338","article-title":"Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol.","volume":"23","author":"Carrillo-L\u00f3pez","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R74-22-20230601","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5414\/CNP70126","article-title":"Efficacy of cinacalcet administered with the first meal after dialysis: The SENSOR Study.","volume":"70","author":"Schaefer","year":"2008","journal-title":"Clin Nephrol"},{"key":"R75-22-20230601","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ceca.2003.10.008","article-title":"Calcium-sensing receptor in the brain.","volume":"35","author":"Yano","year":"2004","journal-title":"Cell Calcium"},{"key":"R76-22-20230601","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/039139880903200208","article-title":"Calcimimetics in the chronic kidney disease-mineral and bone disorder.","volume":"32","author":"Bover","year":"2009","journal-title":"Int J Artif Organs"},{"key":"R77-22-20230601","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.semnephrol.2014.10.001","article-title":"Calcium-sensing receptor activation in chronic kidney disease: Effects beyond parathyroid hormone control.","volume":"34","author":"Massy","year":"2014","journal-title":"Semin Nephrol"},{"key":"R78-22-20230601","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/j.1523-1755.2005.310_1.x","article-title":"High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism.","volume":"67","author":"Touam","year":"2005","journal-title":"Kidney Int"},{"key":"R79-22-20230601","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2215\/CJN.05970809","article-title":"Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content.","volume":"5","author":"Bushinsky","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R80-22-20230601","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.110.178681","article-title":"Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.","volume":"337","author":"Henley","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R81-22-20230601","doi-asserted-by":"crossref","first-page":"G78","DOI":"10.1152\/ajpgi.00036.2003","article-title":"Regulation of the epithelial Ca2+ channels in small intestine as studied by quantitative mRNA detection.","volume":"285","author":"van Abel","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R82-22-20230601","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/ndt\/gfs404","article-title":"Control of mineral metabolism and bone disease in haemodialysis patients: Which optimal targets?","volume":"28","author":"Fouque","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R83-22-20230601","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R86-22-20230601","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2215\/CJN.04650512","article-title":"The case for routine parathyroid hormone monitoring.","volume":"8","author":"Sprague","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R87-22-20230601","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2215\/CJN.10231012","article-title":"Rebuttal: the case for routine parathyroid hormone monitoring.","volume":"8","author":"Goldsmith","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R88-22-20230601","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R89-22-20230601","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/ndt\/gfq304","article-title":"Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.","volume":"26","author":"Naves-D\u00edaz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R90-22-20230601","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/kisup.2013.94","article-title":"A Japanese approach for CKD-MBD.","volume":"3","author":"Yokoyama","year":"2013","journal-title":"Kidney Int Suppl (2011"},{"key":"R91-22-20230601","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2009.374","article-title":"Parathyroid hormone measurement in CKD.","volume":"77","author":"Souberbielle","year":"2010","journal-title":"Kidney Int"},{"key":"R93-22-20230601","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1525-139X.2010.00823.x","article-title":"Target levels for serum phosphorus and parathyroid hormone.","volume":"24","author":"Qunibi","year":"2011","journal-title":"Semin Dial"},{"key":"R94-22-20230601","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study.","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R95-22-20230601","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2215\/CJN.02110310","article-title":"Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.","volume":"5","author":"Komaba","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R96-22-20230601","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000357951","article-title":"Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: Histological and cytological analyses.","volume":"124","author":"Tatsumi","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"R97-22-20230601","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ckj\/sft026","article-title":"Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction.","volume":"6","author":"Zitt","year":"2013","journal-title":"Clin Kidney J"},{"key":"R98-22-20230601","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.","volume":"27","author":"Koizumi","year":"2012","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201601000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:40Z","timestamp":1786369540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201601000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01760215","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}